QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.104.001701v1 33/1/23    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamanaka, H. Articles by Yokoi, T. Search for Related Content PubMed PubMed Citation Articles by Yamanaka, H. Articles by Yokoi, T.

TRANS-3'-HYDROXYCOTININE O- AND N-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES

Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science (H.Y., M.N., M.K., T.Y.) and Synthetic Organic Chemistry, Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology (A.K., O.T., H.I.) Kanazawa University, Kanazawa, Japan

Trans-3'-hydroxycotinine is a major metabolite of nicotine in humans and is mainly excreted as O-glucuronide in smoker's urine. Incubation of human liver microsomes with UDP-glucuronic acid produces not only trans-3'-hydroxycotinine O-glucuronide but also N-glucuronide. The formation of N-glucuronide exceeds the formation of O-glucuronide in most human liver microsomes, although N-glucuronide has never been detected in human urine. Trans-3'-hydroxycotinine N-glucuronidation in human liver microsomes was significantly correlated with nicotine and cotinine N-glucuronidations, which are catalyzed mainly by UDP-glucuronosyltransferase (UGT)1A4 and was inhibited by imipramine and nicotine, which are substrates of UGT1A4. Recombinant UGT1A4 exhibited substantial trans-3'-hydroxycotinine N-glucuronosyltransferase activity. These results suggest that trans-3'-hydroxycotinine N-glucuronidation in human liver microsomes would be mainly catalyzed by UGT1A4. In the present study, trans-3'-hydroxycotinine O-glucuronidation in human liver microsomes was thoroughly characterized, since trans-3'-hydroxycotinine O-glucuronide is one of the major metabolites of nicotine. The kinetics were fitted to the Michaelis-Menten equation with a K_m of 10.0 ± 0.8 mM and a V_max of 85.8 ± 3.8 pmol/min/mg. Among 11 recombinant human UGT isoforms expressed in baculovirus-infected insect cells, UGT2B7 exhibited the highest trans-3'-hydroxycotinine O-glucuronosyltransferase activity (1.1 pmol/min/mg) followed by UGT1A9 (0.3 pmol/min/mg), UGT2B15 (0.2 pmol/min/mg), and UGT2B4 (0.2 pmol/min/mg) at a substrate concentration of 1 mM. Trans-3'-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7 increased with an increase in the substrate concentration up to 16 mM (10.5 pmol/min/mg). The kinetics by recombinant UGT1A9 were fitted to the Michaelis-Menten equation with K_m = 1.6 ± 0.1 mM and V_max = 0.69 ± 0.02 pmol/min/mg of protein. Trans-3'-hydroxycotinine O-glucuronosyltransferase activities in 13 human liver microsomes ranged from 2.4 to 12.6 pmol/min/mg and were significantly correlated with valproic acid glucuronidation (r = 0.716, p < 0.01), which is catalyzed by UGT2B7, UGT1A6, and UGT1A9. Trans-3'-hydroxycotinine O-glucuronosyltransferase activity in human liver microsomes was inhibited by imipramine (a substrate of UGT1A4, IC₅₀ = 55 µM), androstanediol (a substrate of UGT2B15, IC₅₀ = 169 µM), and propofol (a substrate of UGT1A9, IC₅₀ = 296 µM). Interestingly, imipramine (IC₅₀ = 45 µM), androstanediol (IC₅₀ = 21 µM), and propofol (IC₅₀ = 41 µM) also inhibited trans-3'-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7. These findings suggested that trans-3'-hydroxycotinine O-glucuronidation in human liver microsomes is catalyzed by mainly UGT2B7 and, to a minor extent, by UGT1A9.

This article has been cited by other articles:

				T. R. Gray, R. Magri, D. M. Shakleya, and M. A. Huestis Meconium Nicotine and Metabolites by Liquid Chromatography-Tandem Mass Spectrometry: Differentiation of Passive and Nonexposure and Correlation with Neonatal Outcome Measures Clin. Chem., December 1, 2008; 54(12): 2018 - 2027. [Abstract] [Full Text] [PDF]

				H. Yamanaka, M. Nakajima, M. Katoh, and T. Yokoi Glucuronidation of Thyroxine in Human Liver, Jejunum, and Kidney Microsomes Drug Metab. Dispos., September 1, 2007; 35(9): 1642 - 1648. [Abstract] [Full Text] [PDF]